Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Britain Courts Anthropic Amid US Defense Department Dispute 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Apple Turns 50: From Garage Startup to AI Crossroads 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
COLORADO SPRINGS, Colo., Oct. 06, 2016 -- The Spectranetics Corporation (Nasdaq:SPNC) today announced that the Company will release third quarter 2016 financial results after the market close on Thursday, October 27, 2016. Company management will host a conference call beginning at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) to discuss the results. The dial-in for the conference call is (877) 561-2747 for domestic callers or (973) 409-9689 for international callers, and the Conference ID is 89698306. There will also be a live webcast of the call on the investor relations section of the Company’s website at www.spectranetics.com, which will be available on the Company’s website for 14 days following the completion of the call.
Additionally, the Company announced that it will host a physician panel and Q&A session with Company management at the Transcatheter Cardiovascular Therapeutics conference in Washington, D.C., on November 2, 2016, following the release of the ILLUMENATE Pivotal study. The event will begin at 10:00 a.m. Eastern Time. Space will be limited and you must RSVP to [email protected] to reserve a seat. There will also be a live webcast of the event on the investor relations section of the Company’s website at www.spectranetics.com, which will be available on the Company’s website for 14 days following the event.
About Spectranetics
The Spectranetics Corporation develops, manufactures, markets and distributes medical devices used in minimally invasive procedures within the cardiovascular system. The Company's products are available in over 65 countries and are used to treat arterial blockages in the heart and legs and in the removal of pacemaker and defibrillator leads.
The Company's Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above and below the knee, the AngioSculpt scoring balloon used in both peripheral and coronary procedures, and the Stellarex drug-coated balloon peripheral angioplasty platform, which received European CE mark approval in December 2014. The Company also markets support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. The Company markets aspiration and cardiac laser catheters to treat blockages in the heart.
The Lead Management (LM) product line includes excimer laser sheaths, dilator sheaths, mechanical sheaths and accessories for the removal of pacemaker and defibrillator cardiac leads.
For more information, visit www.spectranetics.com.
Investor Relations Contacts Zach Stassen [email protected] (719) 447-2292 Michaella Gallina [email protected] (719) 447-2417
